Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Antiparkinsonian actions of a selective 5-HT1A agonist, tandospirone, in rats

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

Cover image Placeholder

Antiparkinsonian effects of tandospirone, a selective 5-HT1A receptor agonist, were evaluated using rat models of Parkinson's disease. Tandospirone reversed catalepsy induced by the D2 antagonist haloperidol, in a dose-dependent manner. The anti-cataleptic action of tandospirone was comparable to that of bromocriptine and greater than that of L-DOPA. In rats with unilateral dopaminergic lesion by 6-hydroxydopamine, tandospirone markedly induced contralateral rotation. Furthermore, tandospirone dose-dependently restored spontaneous locomotor activity in reserpine-treated rats. These antiparkinsonian effects of tandospirone were abolished by coadministration of WAY-100635, a selective 5-HT1A antagonist, but not by haloperidol. The present results suggest that tandospirone has a therapeutic potential in treating parkinsonian symptoms, which is brought about through activation of 5-HT1A receptor.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation